常任理事

Medicine & Life Sciences

1. Abatacept 14%
2. Adalimumab 17%
3. Adenocarcinoma 15%
4. Anastomotic Leak 11%
5. Anti-Idiotypic Antibodies 11%
6. Antibodies 20%
7. Antigens 11%
8. Antirheumatic Agents 16%
9. Atopic Dermatitis 12%
10. Autoantibodies 31%
11. Autoimmune Diseases 13%
12. B-Lymphocytes 11%
13. baricitinib 18%
14. Biomarkers 15%
15. Blister 13%
16. Bone and Bones 13%
17. Breast Neoplasms 19%
18. Bullous Pemphigoid 17%
19. C-Reactive Protein 11%
20. Carcinoma 15%
21. Chemoradiotherapy 25%
22. Cisplatin 22%
23. Cohort Studies 14%
24. Colorectal Neoplasms 28%
25. Confidence Intervals 11%
26. Coronavirus 12%
27. Databases 11%
28. Desmoglein 1 27%
29. Desmoglein 3 51%
30. Desmogleins 21%
31. Docetaxel 11%
32. Drug Therapy 29%
33. Esophageal Neoplasms 96%
34. Esophageal Squamous Cell Carcinoma 56%
35. Esophagectomy 72%
36. Esophagus 13%
37. filaggrin 11%
38. Fluorouracil 22%
39. Gastrectomy 22%
40. Gastrointestinal Neoplasms 15%
41. Genes 14%
42. Hepatocellular Carcinoma 13%
43. Immunoglobulin G 27%
44. Immunoglobulin G4-Related Disease 15%
45. Incidence 16%
46. Infections 11%
47. Infliximab 13%
48. Interleukin-6 11%
49. Japan 65%
50. Joints 22%
51. Keratinocytes 12%
52. Knee 14%
53. Laminoplasty 14%
54. Laparoscopy 21%
55. Liver 25%
56. Liver Transplantation 28%
57. Living Donors 23%
58. Lung 11%
59. Lymph Node Excision 19%
60. Lymph Nodes 34%
61. Magnetic Resonance Imaging 11%
62. Methotrexate 40%
63. Multicenter Studies 12%
64. Mutation 11%
65. Neoplasm Metastasis 45%
66. Neoplasms 55%
67. Nivolumab 11%
68. Ossification of Posterior Longitudinal Ligament 15%
69. Pancreatic Neoplasms 19%
70. Pemphigus 88%
71. Placebos 17%
72. Pneumonia 11%
73. Postoperative Complications 16%
74. Prospective Studies 12%
75. Recurrence 31%
76. Retrospective Studies 17%
77. Rheumatoid Arthritis 100%
78. Rheumatology 10%
79. Safety 38%
80. Sentinel Lymph Node 30%
81. Serum 23%
82. Skin 25%
83. Spinal Cord 16%
84. Spinal Cord Diseases 13%
85. Spinal Cord Injuries 12%
86. Spine 21%
87. Squamous Cell Carcinoma 10%
88. Stomach 19%
89. Stomach Neoplasms 58%
90. Surgical Wound Infection 13%
91. Survival 32%
92. Systematic Reviews 11%
93. Systemic Lupus Erythematosus 19%
94. T-Lymphocytes 14%
95. Therapeutics 40%
96. Thorax 20%
97. tocilizumab 23%
98. Tomography 11%
99. Transplantation 11%
100. Transplants 19%